NDI-034858 study drug
4858-201
Phase 2 small_molecule completed
Quick answer
NDI-034858 study drug for Moderate to Severe Plaque Psoriasis is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Moderate to Severe Plaque Psoriasis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed